Scalp and Body, Side by Side

Psoriasis may affect the scalp and body simultaneously, but treating these anatomically distinct areas presents different challenges. An analysis of the phase 3 ARRECTOR trial examined patterns of improvement in disease severity and itch with roflumilast foam 0.3% over eight weeks. Along with the primary efficacy findings, the data offer a closer look at how response developed over time at each site. Understanding those trajectories may help clinicians set more informed expectations for patients managing psoriasis in multiple locations.

October 29, 2026

Related CME